Activity Downloads

To Participate

To participate in this continuing education activity:

1. Review the activity description and objectives.
2. View the activity.
3. Complete the online post-test and activity evaluation.

View the other Modules in this CSPE Core Curriculum Series:
  
Hepatitis C Module #1: The abCs of HCV ►

Hepatitis C Module #2: Direct Acting Antivirals for the Treatment of Hepatitis C ►

Hepatitis C Module #3: HCV Drug Therapy Management ►

 

This activity is available for free to members of NASP. Visit the top section of www.ProCE.com/CSPE for details.

A product of the National Association of Specialty Pharmacy's (NASP) Center for Specialty Pharmacy Education(CSPE). View more NASP/CSPE Activities►

Activity Description

Hepatitis C virus (HCV) has become one of the most common infections worldwide. According to the CDC, up to 3.9 million people in the United States may be infected. Healthcare costs associated with this disease have been climbing steadily to make it one of the costliest diseases to treat. Individuals infected with this contagious virus can remain asymptomatic for many years until HCV manifests into a serious clinical presentation. The disease can be acute or chronic ranging from mild to life threating in severity. This comprehensive four module program will provide a complete overview of HCV including disease state info, treatments, therapy selection, monitoring, and future considerations. Module Four will include appropriateness of therapy for special populations, resistance issues, and emerging treatment options. The role of the specialty pharmacist will also be addressed.

Learning Objectives

The target audience for this activity includes pharmacists. Upon completion of this activity, participants will be able to:

• Describe HCV selection and management in special populations.
• Describe common resistance features in HCV.
• Describe the role of specialty pharmacists in the management of special populations and collaborations with the healthcare team.

Faculty

Autumn D. Zuckerman PharmD, BCPS, AAHIVP, CSP
Program Director, Health Outcomes and Research
Vanderbilt Specialty Pharmacy
Vanderbilt University Medical Center
Nashville, Tennessee

Disclosure

It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants the existence of any significant financial interest or any other relationship with the manufacturer of any commercial product(s) discussed in an educational presentation. Autumn Zuckerman does not have any relevant commercial and/or financial relationships to disclose.

CE Accreditation

Release Date: 04-03-2020
Expiration Date: 04-03-2023

Pharmacists

This CE activity is jointly provided by ProCE, Inc. and the National Association of Specialty Pharmacy (NASP). ProCE is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-20-211-H01-P has been assigned to this knowledge-based, home-study activity. This CE activity is approved for 1.25 contact hours (0.125 CEU) in states that recognize ACPE providers. Completion of an evaluation and post-test with a score of 70% or higher is required to receive CE credit. Proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.

Funding

No external support has been received for this activity.

 

The material presented in this CE activity does not reflect the views of ProCE, LLC or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.